Centocor
Executive Summary
Contracts Bio-Pharm Clinical Services to conduct clinical data management and analyses of the biotech company's new Phase III trial required by FDA for Centoxin (HA-1A) in the treatment of septic shock patients ("The Pink Sheet" June 8, T&G-12). In addition, Centocor has hired the law firm of King & Spalding to audit all of the company's PLA filings "to ensure that procedures and protocols are in place to protect the integrity of clinical trial results and identify any deficiencies or discrepancies which may have existed in the past," Centocor said in a June 26 press release. Centocor's MyoScint PLA, recommended for approval in November, also appears to be stalled at FDA. The company has created a Compliance Oversight Committee reporting to the board of directors, which will "oversee the introduction and monitoring of compliance procedures within Centocor operations and to implement any recommendations resulting from the audits," the firm said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth